15 patents currently held
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2036. from the record
Of the 7 now held by other companies, 3 name Legend Biotech USA Inc. as their current owner, and 4 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2036
Next term end
15
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2038 · High confidence
Also notable
Ends Nov 2038 · High confidence
Also notable
Ends Mar 2039 · High confidence
Also notable
Ends Jan 2040 · High confidence
Also notable
Ends Jun 2039 · High confidence
Also notable
Ends Apr 2036 · High confidence
Also notable
Ends Nov 2039 · High confidence
Also notable
Ends Oct 2037 · High confidence
Multispecific Antigen Binding Proteins and Methods of Use Thereof
US 11,447,573
The most cited patent in this portfolio, cited by 9 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
Single-Domain Antibodies and Variants Thereof Against CTLA-4
US 11,472,881
Cited by 8 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
Single-Domain Antibodies and Variants Thereof Against PD-1
US 11,713,353
Granted 2023. Computed term ends 2039.
Novel Chimeric Antigen Receptor and Use Thereof
US 11,564,945
Cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2040.
Single-Domain Antibodies and Variants Thereof Against PD-L1
US 11,673,954
Granted 2023. Computed term ends 2039.
Compositions and Methods for Increasing Protein Half-Life in a Serum
US 10,407,508
Granted 2019. Computed term ends 2036.
Chimeric Antibody Immune Effctor Cell Engagers and Methods of Use Thereof
US 11,827,713
Granted 2023. Computed term ends 2039.
Compositions and Methods Using a Single-Domain Antibody Binding Transferrin and Protein A for Increasing Protein Half-life in Serum
US 11,505,601
Granted 2022. Computed term ends 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for Single-Domain Antibodies and Variants Thereof Against PD-L1 (US 11,673,954) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due Jan 25, 2027The maintenance fee for Antibodies and Variants Thereof Against Tigit (US 11,708,410) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Feb 1, 2027The maintenance fee for Single-Domain Antibodies and Variants Thereof Against PD-1 (US 11,713,353) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due Mar 10, 2027The maintenance fee for Compositions and Methods for Increasing Protein Half-Life in a Serum (US 10,407,508) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Chimeric Antibody Immune Effctor Cell Engagers and Methods of Use Thereof (US 11,827,713) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Single-Domain Antibodies and Variants Thereof Against Tigit (US 11,905,327) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Sep 19, 2027The maintenance fee for Anti-Mesothelin Chimeric Antigen Receptor (CAR) Constructs and Uses Thereof (US 11,932,698) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Single-Domain Antibodies Against LAG-3 and Uses Thereof (US 11,958,903) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
What they patent
The largest of its 15 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,407,508 | Compositions and Methods for Increasing Protein Half-Life in a Serum In force · High confidence | In force | High confidence | |
| US 11,505,601 | Compositions and Methods Using a Single-Domain Antibody Binding Transferrin and Protein A for Increasing Protein Half-life in Serum In force · High confidence | In force | High confidence | |
| US 11,447,573 | Multispecific Antigen Binding Proteins and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,472,881 | Single-Domain Antibodies and Variants Thereof Against CTLA-4 In force · High confidence | In force | High confidence | |
| US 11,713,353 | Single-Domain Antibodies and Variants Thereof Against PD-1 In force · High confidence | In force | High confidence | |
| US 11,673,954 | Single-Domain Antibodies and Variants Thereof Against PD-L1 In force · High confidence | In force | High confidence | |
| US 11,708,410 | Antibodies and Variants Thereof Against Tigit In force · High confidence | In force | High confidence | |
| US 11,827,713 | Chimeric Antibody Immune Effctor Cell Engagers and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,564,945 | Novel Chimeric Antigen Receptor and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,932,698 | Anti-Mesothelin Chimeric Antigen Receptor (CAR) Constructs and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 15: 7 patents in force now held by others · 2 patents ended · 38 applications pending · 19 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.